Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice

Mol Neurobiol. 1995 Aug-Dec;11(1-3):155-63. doi: 10.1007/BF02740692.

Abstract

Administration of methamphetamine (METH) to animals causes loss of DA terminals in the brain. The manner by which METH causes these changes in neurotoxicity is not known. We have tested the effects of this drug in copper/zinc (CuZn)-superoxide dismutase transgenic (SOD Tg) mice, which express the human CuZnSOD gene. In nontransgenic (non-Tg) mice, acute METH administration causes significant decreases in DA and dihydroxyphenylacetic acid (DOPAC) in the striata of non-Tg mice. In contrast, there were on significant decreases in striatal DA in the METH administration caused decreases in striatal DA and DOPAC in the non-Tg mice, but not in the SOD-Tg mice. Similar studies were carried out with 1-methyl-1,2,3,6-tetrahydropyridine (MPTP), which also causes striatal DA and DOPAC depletion. As in the case of METH, MPTP causes marked depletion of DA and DOPAC in the non-Tg mice, but not in the SOD Tg mice. These results suggest that the mechanisms of toxicity of both METH and MPTP involved superoxide radical formation.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Animals
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Dopamine / metabolism
  • Humans
  • MPTP Poisoning*
  • Methamphetamine / toxicity*
  • Mice
  • Mice, Transgenic
  • Models, Neurological
  • Neurotoxins / toxicity*
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / metabolism*

Substances

  • Neurotoxins
  • 3,4-Dihydroxyphenylacetic Acid
  • Methamphetamine
  • Superoxide Dismutase
  • Dopamine